(EKTA-B) Elekta (publ) - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000163628
EKTA-B: Radiation, Therapy, Software, Brachytherapy, Neurosurgery, Oncology
Elekta AB (publ), a pioneer in medical technology, specializes in developing innovative clinical solutions for cancer and brain disorders. As a leader in radiation therapy, Elekta offers a comprehensive suite of products that cater to diverse oncology needs. Their Elekta Unity stands out as the only FDA-approved MR-guided radiation therapy system, a significant advancement in precision medicine.
The companys product portfolio is robust, featuring the renowned Leksell Gamma Knife for brain metastases, which has set a benchmark in stereotactic radiosurgery. Additionally, Elekta provides brachytherapy solutions like Elekta Studio and Venezia applicators, enhancing treatment options for cervical cancer. Their commitment to innovation extends to software, with Elekta ONE integrating multiple solutions for streamlined cancer care.
Financially, Elekta presents a compelling profile with a market cap of 25,121.96M SEK and a P/E ratio of 25, indicating strong market valuation. The forward P/E of 12 suggests potential undervaluation, offering an attractive entry point for investors. A P/B ratio of 2.43 and P/S of 1.39 further highlight the companys solid financial health and growth prospects.
As a global leader with a strong R&D focus, Elektas integrated solutions position it as a key player in comprehensive cancer care. Their investment in innovation and established market presence make them an attractive consideration for investors seeking exposure to the growing oncology sector. With a proven track record and strategic advancements, Elekta is poised for sustained growth in the medical technology landscape.
Additional Sources for EKTA-B Stock
EKTA-B Stock Overview
| Market Cap in USD | 2,217m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception |
EKTA-B Stock Ratings
| Growth 5y | -39.2% |
| Fundamental | 19.4% |
| Dividend | 62.4% |
| Rel. Strength Industry | -24.8 |
| Analysts | - |
| Fair Price Momentum | 50.69 SEK |
| Fair Price DCF | 42.74 SEK |
EKTA-B Dividends
| Dividend Yield 12m | 3.98% |
| Yield on Cost 5y | 3.67% |
| Annual Growth 5y | 5.92% |
| Payout Consistency | 90.8% |
EKTA-B Growth Ratios
| Growth Correlation 3m | -8.7% |
| Growth Correlation 12m | -72.2% |
| Growth Correlation 5y | -56.6% |
| CAGR 5y | -3.04% |
| CAGR/Max DD 5y | -0.05 |
| Sharpe Ratio 12m | 0.37 |
| Alpha | -33.26 |
| Beta | 0.82 |
| Volatility | 32.66% |
| Current Volume | 1112k |
| Average Volume 20d | 1153k |
As of March 12, 2025, the stock is trading at SEK 56.00 with a total of 1,112,007 shares traded.
Over the past week, the price has changed by -1.62%, over one month by -12.33%, over three months by -11.17% and over the past year by -23.71%.
Neither. Based on ValueRay Fundamental Analyses, Elekta (publ) is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 19.35 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EKTA-B as of March 2025 is 50.69. This means that EKTA-B is currently overvalued and has a potential downside of -9.48%.
Elekta (publ) has no consensus analysts rating.
According to ValueRays Forecast Model, EKTA-B Elekta (publ) will be worth about 55.9 in March 2026. The stock is currently trading at 56.00. This means that the stock has a potential downside of -0.11%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 70.4 | 25.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 55.9 | -0.1% |